NatImmune Initiates Phase IIb Clinical Study with BAMLET Topical Gel

NatImmune A/S has announced the initiation of a phase IIb clinical trial designed to evaluate the safety and efficacy of its BAMLET Topical Gel, a protein-lipid based proprietary dermatological product candidate, for the treatment of recalcitrant warts in immuno-suppressed kidney-transplanted patient when applied locally to wart lesions.

Approximately a total of 45,000 transplants were performed in the US and EU in 2007, with recipients now living longer with their organs. In the US alone, the prevalence of living organ-transplant recipients is approximately 200,000.

The phase IIb clinical trial, which will be conducted at several dermatology centres and clinics in Denmark, will enrol approximately 120 patients in the double-blinded, placebo-controlled trial investigating two concentrations of BAMLET. The drug will be applied once daily for 8 weeks to selected wart lesions on each patient. The primary objective of the study is to evaluate efficacy of BAMLET based on reduction in area of each lesion. In addition, secondary objectives include evaluations of resolution/clearance, time-to-resolution, and recurrence of the treated warts and tolerability of the product.

For further information please contact:

Martin Bonde,

CEO

Tel: +45 39 17 94 44

Email: mb@natimmune.dk

Or visit: www.natimmune.com